Company news
Abl Diagnostics Sa (EURONEXT:ABLD) news
Every Abl Diagnostics Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report
September 14, 2026
ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen
September 11, 2026
ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partn...
September 10, 2026
ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Inc...
September 8, 2026
ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 – Arrangements for the Availability and Consultation of...
August 27, 2026
ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Number of Shares Constituting the Share Capital
August 27, 2026
ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris
August 7, 2026
ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alum...
July 27, 2026
ABL Diagnostics Informed that its Reference Shareholder ABL Has Crossed Below the 95% Threshold
July 15, 2026
ABL Diagnostics – Approval of Dividend Distribution for Fiscal Year 2025
July 2, 2026
ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031
June 12, 2026
ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France
June 10, 2026
ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Total Number of Shares Composing the Share Capital
June 9, 2026
ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 – Terms for Making Available or Consulting Preparatory Docum...
June 9, 2026
ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL
June 5, 2026
ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026
June 1, 2026
ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025
May 18, 2026
ABL Diagnostics annonce le développement d’un nouveau panel syndromique intégrant la détection du hantavirus par PCR
May 12, 2026
ABL Diagnostics Reports Historic 2025 Annual Results: Net Income Explosion (+246%), Strong Operating Profitability and Global Acceleration
May 11, 2026
ABL Diagnostics: Availability of the 2025 Annual Financial Report
May 7, 2026
ABL Diagnostics Announces Two New Scientific Publications, Reinforcing its Expertise in HIV Sequencing-based Genotyping
April 13, 2026
ABL Diagnostics Expands HIV Sequencing Expertise into TB Drug Resistance Profiling with New NGS Solutions
March 20, 2026
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
March 17, 2026
ABL Diagnostics Update Regarding Non-Binding Letter of Intent
February 19, 2026
ABL SA Executes the First Purchase Notice of ABL Diagnostics Shares With Alumni Capital
February 13, 2026
ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Rev...
December 19, 2025
Information on a Temporary Transfer of ABL Diagnostics Shares
December 5, 2025
ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market
November 14, 2025
ABL Diagnostics – Announcement of a Second Agreement Between ABL SA and Alumni Capital
October 22, 2025
ABL Diagnostics: Switch to Continuous Trading on Euronext Paris as From November 3rd, 2025
October 16, 2025